Related Experiment Video
Updated: May 5, 2026
06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.2K
Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Severe Ischemic Left Ventricular Systolic
Ruth A Mathew Kalathil1, Akshay Machanahalli Balakrishna2, Ahmed El-Shaer1
1Department of Medicine, Creighton University School of Medicine, Omaha, NE.
Summary
Percutaneous coronary intervention (PCI) did not reduce all-cause mortality in patients with severe left ventricular systolic dysfunction (LVSD). Optimal medical therapy alone showed similar survival outcomes for these patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Heart Failure Research
Background:
- Coronary artery disease (CAD) is a primary cause of heart failure and a leading cause of cardiovascular death globally.
- Severe ischemic left ventricular systolic dysfunction (LVSD) presents treatment challenges due to limited evidence supporting percutaneous coronary intervention (PCI).
Purpose of the Study:
- To compare the efficacy of PCI versus optimal medical therapy (OMT) alone in patients with severe ischemic LVSD.
- To evaluate the impact of PCI on all-cause mortality in this patient population.
Main Methods:
- A meta-analysis was conducted using data from PubMed, EMBASE, and ClinicalTrials.gov up to December 2023.
- Included were four studies (two randomized controlled trials) with 2080 patients (1082 PCI, 998 OMT).
- Random effects models were used to calculate pooled incidence and relative risk for all-cause mortality.
Main Results:
- All-cause mortality did not differ significantly between the PCI group (15.5%) and the OMT group (20.0%).
- The relative risk for all-cause mortality in the PCI group was 0.88 (95% CI, 0.75-1.09; P=.25).
Conclusions:
- Current evidence suggests PCI does not improve all-cause mortality in patients with severe LVSD who do not have lifestyle-limiting anginal symptoms.
- Further research is necessary to identify specific patient subgroups that may benefit more from PCI or OMT.
Related Concept Videos
01:26Mitral Stenosis III: Medical Management
538
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
538
01:14Myocarditis III: Medical Management
344
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
344
01:28Acute Coronary Syndrome IV: Interprofessional Care
525
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
525
01:30Cardiomyopathy II: Dilated Cardiomyopathy
798
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
798
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
810
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810
01:29Cardiomyopathy V: Interprofessional Care
761
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
761